Key result
Repeated dosing of ketoprofen in end-stage renal disease patients resulted in a 2.7-3.8 fold accumulation of S-ketoprofen and its glucuronide, indicating futile cycling.
Why the study?
Does ketoprofen administration lead to futile cycling and accumulation of enantiomers in patients with end-stage renal disease?
Does ketoprofen administration lead to futile cycling and accumulation of enantiomers in patients with end-stage renal disease?
In patients with end-stage renal disease, repeated dosing of ketoprofen leads to selective accumulation of the S-enantiomer due to futile cycling, increasing systemic exposure.
Alerts to accumulation risk with repeated dosing in ESRD; leaves open confirmation in larger pharmacokinetic trials.
AIMS: To assess if futile cycling of ketoprofen occurs in patients with decreased renal function. METHODS: Ketoprofen was administered to six haemodialysis-dependent patients with end-stage renal disease as single (50 mg) or multiple doses (50 mg three times daily, for 7 days). Plasma and dialysate concentrations of the unconjugated and glucuronidated R- and S-enantiomers of ketoprofen were determined using h.p.l.c. following the single and multiple dosing. RESULTS: The oral clearance was decreased and terminal elimination half-lives of R- and S-ketoprofen and the corresponding acyl glucuronides were increased in functionally anephric patients compared with healthy subjects. In contrast with the R-isomers, S-ketoprofen and S-ketoprofen glucuronide exhibited an unexpected accumulation (2.7-3. 8 fold) after repeated dosing achieving S:R ratios of 3.3+/-1.7 and 11.2+/-5.3, respectively. The plasma dialysis clearances for R- and S-ketoprofen glucuronides were 49.4+/-19.8 and 39.0+/-15.9 ml min-1, respectively, and 10.8+/-17.6 and 13.3+/-23.5 ml min-1 for unconjugated R- and S-ketoprofen. CONCLUSIONS: The selective accumulation of S-ketoprofen and its acyl glucuronide are consistent with amplification of chiral inversion subsequent to futile cycling between R-ketoprofen and R-ketoprofen glucuronide. Severe renal insufficiency, and possibly more modest decrements, results in a disproportionate increase in systemic exposure to the S-enantiomer which inhibits both pathologic and homeostatic prostaglandin synthesis.
No takes yet. Share an insight, caveat, or question.
Grubb et al. (1999) studied End-stage renal disease (n=6). Ketoprofen vs. Healthy subjects was evaluated on Pharmacokinetics of ketoprofen enantiomers (clearance, half-lives, accumulation). Repeated dosing of ketoprofen in end-stage renal disease patients resulted in a 2.7-3.8 fold accumulation of S-ketoprofen and its glucuronide, indicating futile cycling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from British Journal of Clinical Pharmacology